Scott Galloway: GLP-1 Drugs Are the ‘Silver Bullet’ for America’s Health Crisis
New York University professor Scott Galloway suggests investors pivot from volatile high-profile IPOs toward the pharmaceutical sector, specifically targeting companies producing GLP-1 receptor agonists. Following SpaceX’s June 12 IPO, which saw shares fluctuate, Galloway argued in a June 17 Medium post that market demand for the space company is artificially inflated. Instead, he highlights GLP-1 … Read more